Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11100MR)

This product GTTS-WQ11100MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11100MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5578MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ12780MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ13244MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ14399MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ9225MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ7409MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ4906MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ9691MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW